Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory
We came across a bullish thesis on Arrowhead Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on ARWR.
Arrowhead Pharmaceuticals Inc. (ARWR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 10,900,000 | $375,941,000 | +3% | 4.86% |
| 2. | Slate Path Capital David Greenspan | 4,982,000 | $171,829,180 | -5% | 2.66% |
| 3. | Siren L.L.C. Raymond Debbane | 2,669,880 | $92,084,161 | 3.6% | |
| 4. | Driehaus Capital Richard Driehaus | 2,099,398 | $72,408,237 | 0.52% | |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,081,689 | $71,797,454 | +3143% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 500 | $11,000.00 | 36,080 | 2024-04-18 | Filing | |
| $25.00 | 500 | $12,500.00 | 35,580 | 2024-04-10 | Filing | |
| $27.34 | 150 | $4,101.00 | 35,080 | 2024-04-02 | Filing | |
| $27.50 | 850 | $23,375.00 | 34,930 | 2024-03-26 | Filing | |
| $28.00 | 400 | $11,200.00 | 34,080 | 2024-03-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $68.00 | 46 | $3,128.00 | 474,908 | 2026-01-05 | Filing | |
| $64.04 | 2,336 | $149,597.44 | 474,954 | 2026-01-05 | Filing | |
| $62.91 | 5,873 | $369,470.43 | 477,290 | 2026-01-05 | Filing | |
| $62.25 | 900 | $56,025.00 | 483,163 | 2026-01-05 | Filing | |
| $61.12 | 600 | $36,672.00 | 484,063 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 684,889 | $45,469,781 | 0.06% | |
| 2. | 324,251 | $21,565,934 | 0.02% | |
| 3. | 286,146 | $18,997,233 | 0.03% | |
| 4. | 63,300 | $4,202,487 | 0.07% | |
| 5. | 22,000 | $1,460,580 | 0.08% |
News See All
Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR)
On December 17, 2025, TheFly reported that Piper Sandler maintained its Overweight rating for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) and lifted its price objective from $70 to $100.
Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval
Arrowhead Pharmaceuticals soared to a new three-year high on Wednesday, as investors took heart from its impressive earnings performance for the full fiscal year, alongside the Food and Drug Administration...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2025 Earnings Call Transcript November 25, 2025Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
11 Best Stocks to Buy for the Next 3 Months According to Hedge Funds
On September 6, Rebecca Patterson, Chief Investment Strategist at Bridgewater Associates, appeared in an interview on CNBC to discuss the current US economy.
Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue
Arrowhead Pharmaceuticals soared by 24.9 percent week-on-week as investors welcomed the company’s receipt of $100 million in payments from Sarepta Therapeutics Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics for diseases with high unmet medical needs.
11 Best Future Stocks to Buy Now
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars.
Hedge Fund Resource Center Billionaire Hedge Funds
